The battle for a vaccine against the pneumococcus pneumoniae has been won, with the US Food and Drug Administration allowing the first batch of shots to be given in the US.
The shots are part of a larger effort to vaccinate a small number of people to combat a pandemic.
The approval came just weeks after the US Government announced that the country would have more than one million people vaccinated by March 1, which is a target date.
The government also said the US would have about 7 million people with the pneumophilus vaccine by May.
There have been fears that the vaccines could be too expensive, especially in the developing world.
US Secretary of Health and Human Services Sylvia Burwell has warned the country’s health system that the cost of vaccines could double in the next year, with a further increase after that.
Ms Burwell said the costs could double again within five years.
“The costs of vaccines for people in developing countries could double or triple again by 2020,” she said.
“We have a pandemics, we have a disease, and we need to make sure that the resources are available to address that.”
The challenge now is to make that transition to a much less expensive vaccine that’s available in our country.
That’s why the vaccine will be made in the United States and we will make it available in other countries,” she added.
Ms Burns also announced that a $4 billion plan to expand access to pneumococcid shots to as many as 70 million people was now underway.
This would mean about 3.5 million people will have access to the shots by the end of 2021.
More than 5 million people have been vaccinated against the virus in the UK, where the first shot was given on 1 March.
The first shot is due to be delivered in March 2021, followed by a second one in March 2022.
The third shot is planned for 2020.
In Australia, the first shots are due to arrive in March 2020.
The vaccine has been tested in countries like Japan, where it is currently available for use. “
Pneumococcal infection has been declining in the developed world, but the pandemic has put the burden on developing countries to increase their immunisation coverage and make sure they get the vaccine, which could mean that the first dose could be postponed until the pandemias ends,” Dr Daniel Breslin, chief medical officer of Australian Vaccination Agency, told the ABC.
The vaccine has been tested in countries like Japan, where it is currently available for use.
The WHO has been testing the vaccine in Europe, but so far only tested the US and Japan.
The new shots will not be available to the UK unless they are approved for use in the country.
A further round of testing is planned to be carried out in the first half of 2020.
“There are many factors in play, including the impact of the pandics, that are going to affect the efficacy and safety of this vaccine, so the first phase of the testing is a bit more intensive and will take place in 2019,” Dr Breslins research director, Professor Simon O’Connell, said.
The US also approved the first injection of a pneumococcoid vaccine, this time a shot containing a pneumophila glycoprotein (PGP) that has been found to be effective against the bacteria.
The PGP vaccine has also been tested against a pneumococcid strain of pneumococci, but no vaccine is available to treat this strain.
The World Health Organization (WHO) has been working to develop a vaccine that could treat the pneumocococcids common cause of pneumonia.
However, it is not yet clear how this vaccine would work.